Infectious diseases remain one of the greatest challenges to global public well being, with pathogens continuing to evolve, re-emerge, and threaten populations. At Genevac Vaccines, we are committed to developing cutting-edge vaccines that protect against both widespread infectious agents and high-consequence biothreats.
💉 Tackling Influenza: An Ongoing Global Priority
Influenza is one of the most persistent and underestimated global burdens. Despite annual vaccination campaigns, seasonal flu causes:
- 3 to 5 million cases of severe illness
- 290,000 to 650,000 respiratory-related deaths globally (WHO estimates)
- Significant economic loss through hospitalizations, workforce absenteeism, and productivity decline
What makes influenza uniquely challenging is its antigenic drift and shift, requiring constant updates to vaccine strains. At Genevac, we are focused on:
- Enhanced adjuvant formulations to improve immune response
- Broader-spectrum influenza vaccines targeting conserved viral components
- Scalable production platforms for rapid deployment during outbreaks or pandemics
Our goal is to contribute to a universal flu vaccine that provides long-term protection across multiple subtypes—minimizing yearly guesswork and maximizing immunity.
🛡️ The Persistent Threat of Smallpox: Biodefense Through Preparedness
Though eradicated in 1980, smallpox remains a Category A bioterrorism threat. Unlike natural epidemics, bioterror attacks with smallpox could lead to:
- High fatality rates (~30%)
- Rapid human-to-human transmission
- Global panic and system overload
Smallpox is stable, easily disseminated, and no longer circulating—making most of the population immunologically naïve. At Genevac, we are addressing this risk through:
- Development of next-generation orthopoxvirus vaccines
- Platforms adaptable for rapid manufacturing and deployment
- Strategies to generate robust humoral and cellular immune responses with minimal adverse effects
We collaborate with international biodefense agencies to support vaccine stockpiling and ensure readiness for high-impact biological threats.
🌐 Our Approach: Innovation Meets Urgency
Genevac Vaccines is structured around three pillars of scientific development:
- Modern Platforms Including mRNA, protein subunit, and viral vector technologies for flexible vaccine design and quick adaptation.
- High-Risk Pathogens Focus Targeting both high-prevalence diseases like influenza and low-frequency, high-impact agents like smallpox, meningococcus, or TBE virus.
- Global Accessibility Optimizing formulations for stability, ease of transport, and low-resource deployment, including lyophilized formats and needle-free systems.
🚀 Beyond Protection: Shaping the Future of Vaccine Science
At Genevac Vaccines, we believe that protecting human health means anticipating threats before they escalate. Whether it's seasonal viruses or engineered pathogens, our research is guided by evidence, powered by technology, and driven by the mission to prevent, protect, and prepare.
